worry

vzphotos/iStock Editorial via Getty Images Cerevel Therapeutics (NASDAQ:CERE) fell 5.5% as investors wait to hear if the Federal Trade Commission will approve its planned $8.7 billion sale to AbbVie (NYSE:ABBV). The deal spread is the widest since the transaction was announced in early December. While there was no specific reasonContinue Reading